ArticleJournal of the Endocrine Society2026
Burosumab treatment in an adult with FGF23-mediated hypophosphatemia due to cutaneous skeletal hypophosphatemia syndrome.
Laura L Tosi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.